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ABSTRACT
Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-
mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is a natural molecule that blocks IL-1α activity by
occupying the IL-1 receptor. The effect of endogenous IL-1Ra levels on the effectiveness of bermekimab is
unknown. We investigated whether pre-treatment levels of circulating IL-1Ra, assessed by an enzyme-linked
immunoassay, correlated with achievement of the primary outcome endpoint (effect on lean bodymass and
symptoms at week 8) in a Phase III study (2:1 randomization) of bermekimab versus placebo (each with best
supportive care) in advanced colorectal cancer. Patients who responded to bermekimab in terms of
achieving the primary endpoint had lower levels of IL-1Ra than non-responders (N = 204 patients; median
= 843 vs. 1035 pg/ml, p=0.0092); no such relationship was observed in the placebo arm (N = 100 patients;
901 vs. 984 pg/ml, p = 0.55). Multivariate analysis corroborated that, in the bermekimab group, patients with
lower baseline IL-1Ra levels were more likely to achieve the primary endpoint (odds ratio (OR) 1.7 (95%
confidence interval (CI), 1.1 to 2.6), p = 0.017); in contrast, in the placebo arm, pre-treatment plasma IL-1Ra
levels were not associated with outcome (OR 1.2 (95% CI 0.6 to 2.5), p = 0.57). The current findings
demonstrate that, in a randomized phase III trial, patients with advanced colorectal cancer and lower levels
of circulating IL-1Ra are more responsive to treatment with the IL-1α-targeting antibody bermekimab and
these observations define a potential biomarker for anti-IL-1α therapy.
ARTICLE HISTORY
Received 10 July 2018
Revised 7 November 2018
Accepted 14 November 2018
KEYWORDS
Interleukin-1; interleukin-1
receptor antagonist;
bermekimab; cancer;
colorectal
Introduction
The interleukin-1 (IL-1) family is a group of 11 cytokines that
play a key role in the regulation of inflammatory and immune
responses to both infectious and non-infectious insults. IL-1α
and IL-1β bind to the same receptor molecule – -the type I IL-
1 receptor (IL-1RI). There is a third ligand of this receptor –
IL-1 receptor antagonist (IL-1Ra). IL-1Ra functions as
a classic receptor antagonist and thereby prevents down-
stream signaling in the presence of its agonists IL-1α and
IL-1β. Moreover, the affinity of IL-1Ra for the IL-1RI is
greater than that for IL-1α and IL-1β. IL-1Ra is produced by
various cells including the liver. Many studies report that
elevated levels of circulating IL-1Ra correlate with the severity
of inflammation and infection and also correlate with levels of
circulating IL-6 and C-reactive protein.1,2
Bermekimab (formerly known as MABp1) is a true human
monoclonal antibody that specifically targets IL-1α, an impor-
tant alarmin, which mediates the initiation of sterile inflam-
mation. Bermekimab differs from previous generations of
therapeutic antibodies in that it was cloned directly from
a human B cell (Epstein-Barr virus-immortalized) that was
isolated from a person with endogenous anti-IL-1α
antibodies.3 The IL-1α precursor is constitutively present in
diverse cells of healthy people, including mucosal epithelial
cells, vascular endothelium, and platelets, and in organs such
as the lungs, liver and kidneys. With stimulation such as
moderate stress, hypoxia and activation of macrophages, the
IL-1α precursor is found in the membrane and there acts to
trigger the IL-1/IL-1R1 on adjacent cells. After injury, the IL-
1α precursor is released and transits to the cell surface mem-
brane, where it activates cells harboring the IL-1 receptor.
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Synopsis
In a randomized phase III trial, patients with advanced colorectal cancer and lower levels of circulating IL-1Ra (an endogenous cytokine that blocks IL-1α activity by
occupying the IL-1 receptor) were more responsive to treatment with bermekimab antibody, which neutralizes IL-1α (a key component of the cancer-related
inflammasome). These results suggest that IL-1Ra levels merit further exploration for their clinical utility as a biomarker of responsiveness to IL-1 antagonists such
as bermekimab.
Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/koni.
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This process jumpstarts the sterile inflammation pathway and,
thus, generates a cascade of inflammatory mediators such as
additional cytokines as well as chemokines. The specific
blockade of IL-1α activity should therefore attenuate the
inflammatory cascade in protean diseases of the bones, skin,
cardiac system, and in cancer.4-7 Furthermore, targeting IL-1α
may have a role in conditions such as heart failure and type 2
diabetes.8 The role of inflammation in these two conditions
has only recently been recognized.
Through its non-signaling occupation of the IL-1 receptor,
the natural endogenous biologic antagonist of the IL-1 recep-
tor – IL-1Ra – acts to block the agonist activity of IL-1α. Since
bermekimab targets IL-1α, we investigated whether the circu-
lating levels of IL-1Ra before initiating treatment with berme-
kimab affected the primary outcome (effect on lean body mass
and symptoms) in a Phase III randomized study of bermeki-
mab versus placebo (each with best supportive care (BSC)) in
patients with advanced colorectal cancer.
Methods
Data source: The analysis performed in this study was based
on data obtained from a phase III study with bermekimab in
patients with advanced colorectal cancer.9
Treatment with bermekimab: Pre-treatment levels of circulat-
ing soluble IL-1Ra were measured in patients enrolled in a phase
III study. Patients received an intravenous infusion of 7.5 mg/kg
bermekimab or placebo given every two weeks for eight weeks.9
The primary endpoint was assessed in patients who received at
least one dose of bermekimab or placebo (modified intention-to-
treat population), and was a composite of stable or increased
lean body mass and stability or improvement in two of three
symptoms (pain, fatigue, or anorexia) at week eight compared
with baseline measurements.9 This study was registered with
ClinicalTrials.gov, number NCT02138422 and was approved
by appropriate institutional review boards; all patients signed
informed consent
Overall, 309 patients were randomized 2:1 to receive berme-
kimab plus best supportive care (BSC) (N = 207) or placebo plus
BSC (N = 102). Patients had metastatic colorectal cancer refrac-
tory to standard chemotherapy (including oxaliplatin and irino-
tecan) and a constellation of symptoms/functional impairment
(e.g. pain, fatigue, anorexia, ECOG performance 1 or 2), weight
loss or elevated systemic inflammation.
Measurement of IL-1Ra: Endogenous\plasma IL-1Ra levels
were measured using a commercial enzyme-linked immu-
noassay (ELISA) kit (human IL-1Ra Platinum ELISA from
eBioscience, catalog number BMS2080). Plasma samples
were frozen and stored for batch analysis. The samples were
obtained on day 1 of course 1, immediately prior to the first
dose of either placebo or bermekimab.
In brief, to determine IL-1Ra levels, samples were thawed and
50 µl aliquots were incubated in microtiter wells coated with
anti-human IL-1Ra antibody. Wells were then washed and
detection achieved by adding biotin-conjugated anti-human IL-
1Ra antibody, followed by incubation with Streptavidin-HRP,
and finally by addition of horseradish peroxidase (HRP) sub-
strate solution. A colored product formed in proportion to the
amount of human IL-1Ra present and absorbance was measured
at 450 nm. The lower limit of assay sensitivity is 219 pg/ml.
Measurement of IL-6: Patient serum samples were sub-
jected to an IL-6 ELISA method tested by PPD Global
Central Labs (Belgium) per PPD document number GCL-
LAB-0371 using Quantikine High Sensitivity Human IL-6
Immunoassay Kits (R&D Systems catalog number HS600B).
This assay employs a quantitative sandwich ELISA technique.
In brief, an anti-IL-6 monoclonal antibody is pre-coated onto
a microtiter plate. Standards and samples are pipetted into the
wells and IL-6 is bound by the immobilized antibody. Plates
are washed and an enzyme-linked polyclonal antibody specific
for IL-6 is added to the wells. Plates are washed to remove
unbound antibody-enzyme reagent and a substrate solution is
added to the wells; color develops in proportion to the
amount of IL-6 bound in the initial step. The lower limit of
detection for the IL-6 assay was 0.108 pg/mL.
Statistical Analysis: A multivariate logistic regression
model was used to assess correlation between baseline IL-
1Ra levels and primary outcome. Receiver operating charac-
teristics (ROC) curves that graphed sensitivity versus specifi-
city-related parameters was used to determine optimal cut off
for IL-1Ra in relation to achieving the primary endpoint
Results
Patients
Plasma samples for measurement of IL-1Ra were available for
204 of 207 participants that were assigned treatment with ber-
mekimab and 100 of 102 participants randomized to the placebo
arm. All patients had advanced, metastatic colorectal cancer. The
mean age of patients was 63 years (range, 31 to 84 years). Sixty
one percent of patients were men. The median number of prior
therapies in the metastatic setting was 3 (range, 1 to 19). There
were no significant differences in age, sex distribution, baseline
weight, KRAS mutation status, IL-6 levels, ECOG performance
status or the number of prior lines of therapy in the bermekimab
and placebo arms (Table 1).
Baseline IL-1Ra levels did not differ in patients
randomized to bermekimab or to placebo
IL-1Ra levels (median (interquartile (IQR) range)) in plasma
samples collected immediately prior to the first dosing of sub-
jects in bermekimab or placebo treatment arms were not differ-
ent: 926 (678 to 1500) versus 972 (705 to 1597) (Table 1). Thus
there was no evidence of randomization bias between groups.
Pre-treatment IL-1Ra levels were significantly lower in
patients who achieved the primary endpoint on
bermekimab but not in the placebo group
Pre-treatment plasma IL-1Ra levels were then examined to
determine if there was any association with outcomes, parti-
cularly with respect to achieving the primary endpoint of the
study (Table 2). Since the IL-1Ra levels were expected to be
associated with disease process, an absolutely homogenous
distribution could not be assumed. This was supported by
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the observation of (i) overall high levels of IL-1Ra present in
these subjects compared to literature reports for other healthy
or even cancer populations;8–12 and (ii) the considerable var-
iance among individuals. The median plasma IL-1Ra level for
the intention-to-treat colorectal cancer population (including
patients from both arms) was 947 pg/ml (IQR 684 to 1514 pg/
ml), which is considerably above the 150–300 pg/ml reported
for the healthy population.10–12
For a normal distribution, it would be expected that, for several
standard deviations from the mean, there should be zero distribu-
tion; and this was not the case in the population. In the population
analyzed, there were outliers many standard deviations from the
mean suggesting that parametric methods of analysis (student’s
t-test) that assume normal distribution may be highly unreliable.
Thusmedian values and the non-parametricWilcoxon Rank Sum
methodology were used to compare differences.
Table 1. Pre-treatment IL-1Ra (and IL-6) plasma levels in intent-to-treat population by treatment arm.
All (N = 309) bermekimab plus BSC (N = 207) Placebo plus BSC (N = 102) P value**
Age (years) (Mean ± SD) 63 ± 10 63 ± 10 63 ± 9 0.53
Sex (% women) 122 (39%) 79 (38%) 43 (42%) 0.50
KRAS mutation* (N (%)) 122 (39%) 85 (41%) 37 (36%) 0.42
ECOG 1 (N (%))* 250 (81%) 170 (82%) 80 (78%) 0.44
ECOG 2 (N (%)) 59 (19%) 37 (18%) 22 (22%) 0.44
Baseline weight (kg) Mean = ±SD* 75 ± 18 74 ± 20 76 ± 16 0.40
Serum IL-6 (pg/ml) Mean (± SD)* 13.7 (± 24.0) 14.0 (± 25.6) 13.0 (± 20.6) 0.74
IL-6 testing Total N IL-6 < 10 pg/ml IL-6 ≥ 10 pg/ml p
Placebo 102 68 (67%) 34 (33%) 0.86
bermekimab 207 140 (68%) 67 (32%)
All 309 208 (67%) 101 (33%)
Prior number of chemotherapy regimens (N (%))*
2 84 (27%) 55 (27%) 29 (28%) 0.80
3 89 (29%) 56 (27%) 33 (32%) 0.39
4 63 (20%) 42 (20%) 21 (%) 0.98
5 30 (10%) 23 (11%) 7 (7%) 0.22
≥6 39 (13%) 27 (13%) 12 (12%) 0.70
IL-1Ra Levels All (N = 304) bermekimab plus BSC (N = 204) Placebo plus BSC (N = 102)
Mean ± SD pg/ml 1702 (± 4341) 1791 ± 4926 1521 ± 2809 0.71
Median (IQR) pg/ml 947
(685 to 1513)
926
(678 to 1500)
972
(705 to 1597)
*Not all patients were assessable for all variables
** p value compares cohort treated with bermekimab versus those treated with placebo
Abbreviations: BSC = best supportive care; ECOG = Eastern Cooperative Group (refers to performance status): IL-6 = interleukin-6; IQR = inter-quartile range;
SD = standard deviation
Table 2. IL-1Ra and treatment outcome.
Pre-Treatment Plasma IL-1Ra According to Treatment Arm and Outcome
(Achieved Primary Endpoint) in Intention-to-treat Population
IL-1Ra Levels (pg/ml)
Randomization Arm
Achieved
Primary
Endpoint N (subjects) Median
Quartile
1 Quartile 3 p value* Odds ratio for benefit with low IL1Ra (95% CI) Multivariate p value
Bermekimab No 137 1035 702 1,602 0.0092 1.7 (1.1 to 2.6) 0.017
Yes 67 843 555 1,165
Placebo No 81 984 722 1,638 0.55 1.2 (0.6 to 2.5) 0.57
Yes 19 901 570 1,220
Distribution of primary endpoint achievers across IL-1Ra cut-off value
IL-1Ra Achieved Primary Endpoint
(bermekimab) P = 0.01**
Achieved Primary
Endpoint (Placebo) P = 0.6
<940 pg/ml 43/104 (41%) 10/46 (22%)
≥940 pg/ml 24/100 (24%) 9/54 (17%)
Total 67/204 (33%) 19/100 (19%) P = 0.014**
Number (N) who Achieved primary endpoint (N/total number treated)
IL1-1Ra level Bermekimab (N (%)/total N) Placebo (N (%)/total N)
<940 pg/ml 43/104 (41%) 10/46 (22%)
P value**
Relative Risk (95% CI)
**P = 0.03; Relative Risk (95% CI) = 1.9 (1.05 to 3.45)
≥ 940 pg/ml 24/100 (24%) 9/54 (17%)
P value** Relative Risk (95%
CI)
P = 0.3 (not significant); Relative Risk (95% CI) = 1.44 (0.72–2.87)
*p value by Wilcoxon Rank Sum test (two-tailed)
** p value, Chi Square, two-tailed
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In Table 2, values are presented for the pre-treatment
plasma IL-1Ra levels among patients (stratified by study
arms) that achieved or failed to achieve the primary endpoint.
In the bermekimab arm, pre-treatment IL-1Ra levels were
significantly associated with the primary endpoint. Patients
who had elevated baseline IL-1Ra were less likely to respond
to bermekimab therapy in terms of achieving the primary
endpoint as compared to those with lower baseline IL-1Ra
levels (median = 1035 vs. 843 pg/ml, p = 0.0092). No such
relationship was observed, however, in the placebo arm, med-
ian pre-treatment plasma levels for IL-1Ra were not different
by patients’ outcomes with respect to the primary endpoint
(984 vs. 901 pg/ml, p = 0.55).
Corroborating findings using logistic regression analysis
A univariate logistic regression model was used to further
explore and qualify this association between endogenous IL-
1Ra levels, treatment, and primary outcome in the Phase III
study. A multivariate logistic model was also constructed by
adding baseline covariates (sex and baseline weight) to the
univariate model to identify other independent predictors that
could be associated with the primary outcome. Results were
calculated as odds ratio (OR) with the corresponding 95%
confidence interval (95%CI). Values for plasma IL-1Ra levels
were log transformed prior to entering into the logistic model
and analysis was performed stratified by study groups.
Multivariate regression analysis corroborated the finding
that, in the bermekimab group, patients with lower baseline
levels of IL-1Ra were more likely to achieve clinical response
(OR 1.7 (95% CI, 1.1 to 2.6), p = 0.017) (Table 2). In contrast,
in the placebo arm, pre-treatment plasma IL-1Ra levels did
not show any significant association with achieving the pri-
mary endpoint (OR 1.2 (95% CI 0.6 to 2.5), p = 0.57).
Determining a cut-off value for pre-treatment circulating
IL-1Ra levels for maximum bermekimab responsiveness
Receiver operating characteristics (ROC) cut off of ≤ 940 pg/m
versus ≥ 940 pg/ml for IL-1Ra levels is determined to be
optimal for predicting outcome in bermekimab -treated
patients: A ROC analysis was performed using a logistic
model to determine a cut-off threshold for pre-existing IL-
1ra levels in terms of the impact on responsiveness (with
respect to achieving the primary endpoint) to bermekimab
therapy (Figure 1). Prediction accuracy using the model was
evaluated along with sensitivity and specificity parameters.
The ROC analysis, evaluating the discriminatory ability of
an optimal IL-1Ra cut-off that correctly identifies the clinical
response, demonstrated that a cut-off value for circulating IL-
1ra levels was 940 pg/ml. This cut-off value would be expected
to provide the best combination of sensitivity and specificity
for identifying subjects that would achieve the primary end-
point in response to bermekimab therapy (specificity 0.55,
sensitivity 0.64, AUC 0.61). The logistic regression analysis
demonstrated the cut-off value to be significantly associated
with primary endpoint (unadjusted OR 2.23 (95%CI 1.22 to
4.08), p = 0.009). The association remained after adjusting for
sex and baseline weight (adjusted OR 2.28 (95%CI 1.24 to
4.19), p = 0.0082. AUC 0.64.).
The ROC cut-off value was also used to assess outcome for
subjects randomized to the placebo group. In the placebo
group, baseline IL-1Ra plasma levels in subjects did not pre-
dict outcomes with respect to the primary endpoint of the
study. Not surprisingly, therefore, the IL-1Ra cut-off did not
Figure 1. Receiver operating characteristics curve showing optimum IL-1Ra cut-off for bermekimab treatment response. True positive rate (sensitivity) and
true negative rate (specificity) are plotted on y-axis, and IL-1Ra plotted on X-axis. The optimal cut off for IL-1ra was 940 pg/ml.
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have any impact on outcomes in either univariate (OR 1.39
(95% CI 0.51 to 3.78) p = 0.52) or multivariate analysis when
adjusted for sex and baseline weight (p= 0.60).
A sensitivity analysis for different IL-1Ra cut-off values
was performed in bermekimab-treated population. From this
analysis, the best cut-off obtained was confirmed to be that
which was generated using the ROC method (i.e., 940 pg/ml)
(data not shown).
Validating that bermekimab -treated but not placebo-treated
patients are more likely to achieve primary outcome at ROC cut
off for IL-1Ra level of 940 pg/ml:The ROC value was then validated
based on the actual IL-1Ra plasma level data and outcomes for
subjects using the cut-off value (<940 vs. ≥940) (Table 2). Using
the ROC value and study findings, the sensitivy of IL-1RA for
predicting responders (true positives or probability that respon-
ders will have IL-1Ra cut-off below 940 pg/ml) for the model was
found to be 0.64. Conversely, the specificity (true negatives or
probability that non-responders will have IL-1Ra values
≥940 pg/ml) for the model was 0.55. Positive predictive value
(the proportion of patients with IL-1Ra <940 pg/ml that achieved
the endpoint) was 0.41; negative predictive value (proportion of
patients with IL-Ra levels ≥940 pg/ml that did not achieve the
endpoint) was 0.76.
When using the optimized cut off from the ROC curve
(<940 pg/ml versus ≥ 940 pg/ml for IL-1ra level), bermeki-
mab-treated patients with low IL-1Ra were more likely to
achieve the study endpoint (41% versus 24%; p = 0.01)
while there was no difference in rate of endpoint achievement
relative to the optimized cut off in patients receiving placebo
(22% versus 17%; p = 0.6) (Table 2). Finally when comparing
bermekimab- versus placebo-treated patients with <940 pg/ml
of IL-1Ra, the former were more likely to achieve the study
endpoint (relative risk (95% CI) = 1.9 (1.05 to 3.45); P = 0.03).
There was no difference in likelihood of achieving the study
endpoint between bermekimab- and placebo-treated patients
for the group with IL-1Ra levels ≥ 940 pg/ml (relative risk
(95% CI) = 1.44 (0.72–2.87); p = 0.3).
IL-6 levels
Because mechanisms inducing various cytokine-related mole-
cules may be similar and because IL-6 is pertinent to features of
many malignancies, we also examined IL-6 levels (plasma sam-
ples for measurement of IL-6 were available for 207 patients in
the bermekimab-treated group and for 102 patients in the
placebo group). IL-6 levels did not differ in the treatment
versus placebo group at baseline (Table 1). As with IL-1Ra,
achievement of the primary endpoint was associated with lower
IL-6 levels in bermekimab-treated patients versus the placebo
group (38% versus 16% of patients with low IL-6 in each arm
achieved the endpoint; p = 0.002); in patients with higher IL-6
levels, there was no difference in the rate of achieving the
primary endpoint (28% versus 22%; p = 0.36) (Table 3).
Discussion
We investigated pre-treatment levels of circulating IL-1Ra in
patients with advanced colorectal cancer entering a double-
blind, placebo-controlled Phase III study of bermekimab (9).
Since IL-1Ra is an endogenous antagonist of IL-1α activity,
examining baseline levels of the antagonist could provide
insight into response to an exogenous IL-1α inhibitor –
bermekimab.
Here we report a significant correlation between circulating
IL-1Ra levels and primary outcomes of patients with colorectal
cancer treated with bermekimab. Baseline IL-1Ra levels were
significantly lower in patients who responded to bermekimab
therapy than in those who did not (median, 843 vs. 1035 pg/ml,
p = 0.0092, adjusted logistic model p = 0.017) (with response
denoting, per protocol, stable or higher lean body mass and
stability or improvement in two of three symptoms (anorexia,
fatigue or pain) at week eight compared with pre-treatment
assessments9). A correlation between IL-1Ra levels and out-
comes was not, however, seen in the placebo arm (p = 0.60,
multivariate logistic model): pre-treatment levels of circulating
IL-1Ra were not different between those achieving or not achiev-
ing the primary outcome in the placebo arm.
The finding that pre-treatment IL-1Ra levels correlated
with primary outcomes in the bermekimab treatment group,
but not in the placebo group, provides evidence that: (i) the
mechanism of action for bermekimab in vivo involves target-
ing IL-1α; and (ii) bermekimab-specific targeting of IL-1α is
indeed related to the effect on primary outcomes achieved in
the Phase III clinical study.9
IL-1 is a central mediator of innate immunity and
inflammation.10 Not surprisingly, therefore, IL-1Ra and
other IL-1 family members play a role in disease progression
in solid and hematological malignancies.5,12–14 In colorectal
cancer, for instance, levels of circulating IL-1Ra are elevated
and associated with clinicopathological features of disease,
including tumor burden and metastasis.6,7 The data are
consistent with our study, which showed median IL-1Ra
levels of 947 pg/ml; this level is significantly higher than
the 150–300 pg/ml found in healthy people.10-12 Of interest,
mutated RAS genes mediate autocrine IL-1β production in
some leukemias by stimulating signal transduction pathways
that activate the IL-1β promoter.15 Furthermore, anti-
inflammatory therapy with canakinumab, which targets IL-
1β, significantly reduced incident lung cancer and lung can-
cer mortality.16
Results from animal models and additional clinical find-
ings support the notion that elevated IL-1Ra levels would
antagonize disease progression in cancer.4,17 In advanced col-
orectal cancer, circulating IL-1Ra levels could act as a natural
inhibitor of tumor-mediated IL-1α activity.17-19 The physio-
logical response to the tumor, including upregulation of cir-
culating IL-1Ra, is likely an important mechanism of
Table 3. Correlation of IL-6 levels and achievement of primary endpoint.
Number (N) who Achieved primary endpoint (N/total number treated)
bermekimab (N/total
N, (%))
Placebo (N /total
N, (%))
Total
(N) P value
IL-6 level
<10 pg/ml
39/104 (38%) 8/51 (16%) 155 0.002
IL-6 level
≥10 pg/ml
29/103 (28%) 11/51 (22%) 154 0.36
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antagonizing disease progression. However, over time, endo-
genous IL-1α antagonism could be expected to exert selection
pressure on the tumor with respect to the dependence on IL-1
signaling. This selection pressure could result in the out-
growth of a tumor phenotype that is less susceptible to IL-
1α antagonism. Alternatively, endogenous IL-1Ra might dam-
pen the response of non-tumor cells in the vicinity of the
malignancy. When tumors enlarge and the vascularization
fails to sufficiently supply them, the tumor cells become
stressed (due to hypoxia) and release IL-1alpha. With contin-
ued stress due to hypoxia, the tumor cells undergo necrotic
death. The released IL-1alpha can now trigger the IL-1R1 on
neighboring cells. This is the “alarmin” property.20 Necrotic
cells thus evoke inflammation, which brings in neutrophils
and inflammatory cells to the area. These effects would be
attenuated in the presence of endogenous IL-1Ra.
The bermekimab monoclonal antibody is derived from
a natural human immune response. Primary sequence analysis
of bermekimab shows that it underwent affinity maturation
in vivo, and consequently has high binding affinity and spe-
cificity for IL-1α.3 The central mechanism of action for ber-
mekimab in vivo is expected to be its neutralization of the
biological activity of IL-1α, including blocking the inflamma-
tory induction of VEGFs and matrix metalloproteinases in
order to inhibit neoangiogenesis and stromal remodeling in
the tumor microenvironment.21 But IL-1α is commonly
expressed on tumor cells where it is associated with invasive-
ness and dedifferentiation.18,19 Consequently, on tumor cells,
IL-1α could act as a target, whereby bermekimab could med-
iate direct inhibition of tumors. As an IgG1 subclass, berme-
kimab activity could include antibody-directed, cell-mediated
cytotoxicity, although there is no current evidence that this
mechanism plays a significant role in the therapeutic activity
of the antibody.
Low IL-6 levels (dichotomized at 10 pg/ml, consistent with
a previous investigation in colorectal cancer22) also tracked with
response in the bermekimab-treated, but not in the placebo-
treated group; 38% versus 16% achieved the primary endpoint
in these groups, respectively (p = 0.002) (Table 3). When patients
were stratified based on baseline IL-6 < 10 pg/ml (low IL-6)
combined with IL-1Ra < 940 pg/ml (low IL-1Ra), the rate of
achieving the primary endpoint was 46% versus 17% for berme-
kimab vs placebo arms, respectively (p = 0.007). It is unclear why
low IL-6 levels would track with responsiveness but, since both
low IL-1Ra and low IL-6 correlated with achievement of the
primary endpoint in bermekimab-treated patients, it is possible
that IL-1Ra and IL-6 have a common pertinent mechanism
underlying their production. Indeed previous studies have sug-
gested that both IL-1Ra and IL-6 increase in response to inflam-
mation and that IL-6 can enhance plasma levels of IL-1Ra.23,24
The current findings confirm a significant association
between pre-treatment circulating IL-1Ra levels and bermeki-
mab responsiveness. Subjects who were relatively “naive” in
terms of IL-1Ra antagonism were more likely to respond to
therapy. The relatively lower level of plasma IL-1Ra could
mean that there are less IL-1R1 occupied by IL-1Ra and this
will make IL-1α (or IL-1β) more likely to be active. The lower
plasma levels also may mean that the patients are not producing
the level they should in response to their cancer and this is
a reflection of why they need more IL-1Ra or more anti-IL-1α
for disease control. Therefore, those who had more elevated pre-
existing antagonist activity had disease progression that was
relatively resistant to pharmacological IL-1α inhibition when
presented with bermekimab. The notion that cell-mediated
immune-surveillance might result in selection pressure on
tumors, particularly as evidenced by loss of HLA expression in
advanced disease, has been suggested (and contested) for several
decades.25 More recently, emergence of defects in interferon-
receptor signaling and in antigen presentation due to selection
pressure has been described as a mechanism of secondary resis-
tance to checkpoint blockade.26 Reports of IL-1Ra association
with various malignancies adds another point of reference to the
immunological and more specifically inflammasome in the nat-
ural history of cancer. The findings presented here provide
important additional evidence that regulators of innate immu-
nity may constitute a mechanism of selection pressure on
tumors. This selection pressure could lead to yet undefined
phenotypic changes that are part of the natural history of the
disease and which possibly impact the effects of treatments that
modulate the inflammatory response to the disease – notably in
this case that of bermekimab.
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